The risk reduction was 40% (aRR = 0.60, 95% CI: 0.37–0.98, P = 0.04) after controlling for age, gender, ethnicity, CCI, DCSI, nephropathy, hyperlipidemia, serum creatinine >2.0 mg/dL, HbA1c and concurrent medications including statins, ACEI, sulfonylurea and insulin, and year of presentation (Table 2). This evidence concerns the gene INS and Nephropathy.